Concepts (281)
Concepts are derived automatically from a person's publications.
Concepts are listed by decreasing relevance which is based on many factors, including how many publications the person wrote about that topic, how long ago those publications were written, and how many publications other people have written on that same topic.
| Name |
Number of Publications
|
Most Recent Publication
|
Publications by All Authors
|
Concept Score
|
Why?
|
|---|
| Bone Neoplasms | 33 | 2023 | 118 | 7.330 |
Why?
|
| Sarcoma | 15 | 2023 | 142 | 2.580 |
Why?
|
| Bone Substitutes | 9 | 2017 | 23 | 2.150 |
Why?
|
| Soft Tissue Neoplasms | 7 | 2022 | 55 | 1.790 |
Why?
|
| Bone Transplantation | 8 | 2017 | 216 | 1.650 |
Why?
|
| Giant Cell Tumor of Bone | 5 | 2022 | 15 | 1.630 |
Why?
|
| Sarcoma, Ewing | 3 | 2020 | 8 | 1.460 |
Why?
|
| Calcium Sulfate | 6 | 2012 | 18 | 1.100 |
Why?
|
| Musculoskeletal Diseases | 2 | 2015 | 44 | 0.940 |
Why?
|
| Limb Salvage | 5 | 2023 | 12 | 0.920 |
Why?
|
| Humans | 61 | 2023 | 26025 | 0.890 |
Why?
|
| Retrospective Studies | 27 | 2023 | 3297 | 0.840 |
Why?
|
| Neoplasm Recurrence, Local | 7 | 2023 | 185 | 0.830 |
Why?
|
| Adult | 24 | 2022 | 7363 | 0.760 |
Why?
|
| Hip Joint | 2 | 2016 | 404 | 0.750 |
Why?
|
| Young Adult | 13 | 2021 | 1853 | 0.740 |
Why?
|
| Adolescent | 16 | 2021 | 2064 | 0.740 |
Why?
|
| Leiomyosarcoma | 1 | 2021 | 21 | 0.730 |
Why?
|
| Osteosarcoma | 8 | 2021 | 35 | 0.710 |
Why?
|
| Child | 13 | 2021 | 1228 | 0.700 |
Why?
|
| Calcium Phosphates | 2 | 2012 | 22 | 0.690 |
Why?
|
| Child, Preschool | 9 | 2021 | 589 | 0.660 |
Why?
|
| Fractures, Bone | 2 | 2012 | 75 | 0.650 |
Why?
|
| Bone Cysts | 2 | 2016 | 2 | 0.650 |
Why?
|
| Synovitis, Pigmented Villonodular | 2 | 2016 | 3 | 0.650 |
Why?
|
| Tibia | 2 | 2010 | 256 | 0.610 |
Why?
|
| Treatment Outcome | 16 | 2023 | 3292 | 0.590 |
Why?
|
| Male | 26 | 2021 | 14008 | 0.580 |
Why?
|
| Middle Aged | 21 | 2021 | 8507 | 0.560 |
Why?
|
| Chondromatosis, Synovial | 1 | 2016 | 4 | 0.550 |
Why?
|
| Arthroplasty, Replacement, Knee | 5 | 2022 | 620 | 0.540 |
Why?
|
| Bone Diseases | 2 | 2017 | 24 | 0.540 |
Why?
|
| Internal Fixators | 1 | 2016 | 38 | 0.530 |
Why?
|
| Female | 23 | 2021 | 14397 | 0.530 |
Why?
|
| Foot | 1 | 2016 | 38 | 0.530 |
Why?
|
| Arthrodesis | 2 | 2014 | 41 | 0.530 |
Why?
|
| Acetabulum | 3 | 2016 | 204 | 0.520 |
Why?
|
| Radiotherapy | 1 | 2016 | 31 | 0.520 |
Why?
|
| Foreign Bodies | 1 | 2016 | 28 | 0.520 |
Why?
|
| Lymphoma, Non-Hodgkin | 1 | 2016 | 37 | 0.510 |
Why?
|
| Ultrasonography, Interventional | 1 | 2016 | 64 | 0.510 |
Why?
|
| Radius | 2 | 2014 | 33 | 0.490 |
Why?
|
| Tobramycin | 2 | 2005 | 9 | 0.460 |
Why?
|
| Knee Prosthesis | 2 | 2008 | 222 | 0.450 |
Why?
|
| Survival Rate | 5 | 2021 | 321 | 0.440 |
Why?
|
| Biopsy | 6 | 2023 | 199 | 0.420 |
Why?
|
| Arthralgia | 2 | 2011 | 115 | 0.420 |
Why?
|
| Anti-Bacterial Agents | 3 | 2022 | 340 | 0.410 |
Why?
|
| Cell Transformation, Neoplastic | 2 | 2010 | 31 | 0.400 |
Why?
|
| Combined Modality Therapy | 3 | 2021 | 277 | 0.390 |
Why?
|
| Chondrosarcoma | 4 | 2023 | 32 | 0.390 |
Why?
|
| Prognosis | 8 | 2023 | 750 | 0.390 |
Why?
|
| Proto-Oncogene Proteins c-akt | 3 | 2017 | 44 | 0.380 |
Why?
|
| Histiocytosis, Sinus | 1 | 2011 | 4 | 0.370 |
Why?
|
| Talus | 1 | 2011 | 16 | 0.370 |
Why?
|
| Allografts | 4 | 2021 | 220 | 0.370 |
Why?
|
| Edema | 1 | 2011 | 24 | 0.370 |
Why?
|
| Follow-Up Studies | 8 | 2022 | 1712 | 0.360 |
Why?
|
| Patellar Ligament | 1 | 2010 | 42 | 0.350 |
Why?
|
| Lung Neoplasms | 2 | 2015 | 505 | 0.340 |
Why?
|
| Humerus | 3 | 2005 | 112 | 0.340 |
Why?
|
| Prosthesis Failure | 4 | 2022 | 506 | 0.330 |
Why?
|
| Osteomyelitis | 3 | 2005 | 19 | 0.320 |
Why?
|
| Debridement | 3 | 2016 | 94 | 0.320 |
Why?
|
| Femur | 4 | 2022 | 382 | 0.320 |
Why?
|
| Reoperation | 6 | 2022 | 873 | 0.300 |
Why?
|
| Bone Plates | 1 | 2008 | 50 | 0.300 |
Why?
|
| Neoadjuvant Therapy | 5 | 2022 | 63 | 0.280 |
Why?
|
| Aged | 12 | 2021 | 8704 | 0.280 |
Why?
|
| Cisplatin | 3 | 2017 | 47 | 0.280 |
Why?
|
| Osteogenesis | 1 | 2007 | 104 | 0.270 |
Why?
|
| Arthroplasty, Replacement, Hip | 3 | 2022 | 788 | 0.260 |
Why?
|
| Curettage | 3 | 2022 | 9 | 0.240 |
Why?
|
| Orthopedic Procedures | 3 | 2004 | 300 | 0.240 |
Why?
|
| Disease-Free Survival | 3 | 2021 | 158 | 0.240 |
Why?
|
| Drug Resistance, Neoplasm | 3 | 2017 | 61 | 0.240 |
Why?
|
| Aged, 80 and over | 6 | 2021 | 4659 | 0.240 |
Why?
|
| Immunohistochemistry | 4 | 2011 | 335 | 0.240 |
Why?
|
| Transplantation, Homologous | 2 | 2004 | 281 | 0.230 |
Why?
|
| Infant | 3 | 2021 | 516 | 0.230 |
Why?
|
| Margins of Excision | 2 | 2022 | 27 | 0.230 |
Why?
|
| Pelvic Bones | 1 | 2004 | 17 | 0.220 |
Why?
|
| Lymphatic Metastasis | 2 | 2021 | 80 | 0.220 |
Why?
|
| Joint Instability | 1 | 2008 | 386 | 0.220 |
Why?
|
| Knee Joint | 2 | 2008 | 743 | 0.220 |
Why?
|
| Spinal Neoplasms | 1 | 2023 | 37 | 0.210 |
Why?
|
| Embolization, Therapeutic | 1 | 2023 | 53 | 0.210 |
Why?
|
| Kidney Neoplasms | 1 | 2023 | 66 | 0.210 |
Why?
|
| Neoplasm Staging | 3 | 2022 | 313 | 0.210 |
Why?
|
| Injections | 2 | 2016 | 44 | 0.210 |
Why?
|
| Neutrophils | 1 | 2023 | 96 | 0.210 |
Why?
|
| Plasma Gases | 1 | 2022 | 2 | 0.210 |
Why?
|
| Prostheses and Implants | 2 | 2015 | 159 | 0.200 |
Why?
|
| Tomography, X-Ray Computed | 4 | 2015 | 713 | 0.200 |
Why?
|
| Absorbable Implants | 1 | 2002 | 24 | 0.200 |
Why?
|
| Apoptosis | 5 | 2022 | 193 | 0.200 |
Why?
|
| Sarcoma, Synovial | 1 | 2022 | 11 | 0.200 |
Why?
|
| Infant, Newborn | 2 | 2021 | 587 | 0.200 |
Why?
|
| Vancomycin | 1 | 2002 | 51 | 0.200 |
Why?
|
| Bone Cements | 3 | 2022 | 88 | 0.200 |
Why?
|
| Radiography | 5 | 2015 | 610 | 0.190 |
Why?
|
| Lymphatic Vessels | 1 | 2021 | 9 | 0.180 |
Why?
|
| Myxosarcoma | 1 | 2020 | 3 | 0.180 |
Why?
|
| Hemipelvectomy | 1 | 2020 | 2 | 0.180 |
Why?
|
| Fibrosarcoma | 1 | 2020 | 9 | 0.180 |
Why?
|
| Pelvic Neoplasms | 1 | 2020 | 4 | 0.180 |
Why?
|
| Orthopedics | 1 | 2002 | 108 | 0.180 |
Why?
|
| Receptor, IGF Type 1 | 2 | 2017 | 17 | 0.170 |
Why?
|
| Hip Prosthesis | 2 | 2022 | 531 | 0.170 |
Why?
|
| Prosthesis-Related Infections | 1 | 2022 | 185 | 0.170 |
Why?
|
| Cell Line, Tumor | 7 | 2017 | 230 | 0.160 |
Why?
|
| Cyclin-Dependent Kinase Inhibitor p27 | 2 | 2016 | 7 | 0.160 |
Why?
|
| Medically Underserved Area | 1 | 2019 | 15 | 0.160 |
Why?
|
| Antineoplastic Agents | 3 | 2017 | 176 | 0.160 |
Why?
|
| Dogs | 4 | 2007 | 176 | 0.160 |
Why?
|
| Chemoradiotherapy | 1 | 2019 | 61 | 0.160 |
Why?
|
| Medical Oncology | 1 | 2019 | 40 | 0.150 |
Why?
|
| Chemotherapy, Adjuvant | 2 | 2010 | 70 | 0.150 |
Why?
|
| Tumor Suppressor Protein p53 | 2 | 2016 | 80 | 0.150 |
Why?
|
| Health Services Accessibility | 1 | 2019 | 99 | 0.150 |
Why?
|
| Osteoarthritis | 1 | 2022 | 316 | 0.150 |
Why?
|
| Healthcare Disparities | 1 | 2019 | 81 | 0.150 |
Why?
|
| Receptors, Somatomedin | 1 | 2017 | 4 | 0.150 |
Why?
|
| Protein Kinase Inhibitors | 2 | 2017 | 45 | 0.140 |
Why?
|
| Antineoplastic Combined Chemotherapy Protocols | 1 | 2019 | 224 | 0.140 |
Why?
|
| Imidazoles | 1 | 2017 | 55 | 0.140 |
Why?
|
| Piperazines | 1 | 2017 | 76 | 0.140 |
Why?
|
| Ceramics | 1 | 2016 | 22 | 0.140 |
Why?
|
| Mechanistic Target of Rapamycin Complex 1 | 1 | 2016 | 10 | 0.130 |
Why?
|
| Synovectomy | 1 | 2016 | 5 | 0.130 |
Why?
|
| Chondroma | 3 | 2012 | 5 | 0.130 |
Why?
|
| Biocompatible Materials | 1 | 2016 | 90 | 0.130 |
Why?
|
| Child Development | 1 | 2016 | 73 | 0.130 |
Why?
|
| Cohort Studies | 1 | 2021 | 1823 | 0.130 |
Why?
|
| Femoral Neoplasms | 1 | 2015 | 4 | 0.120 |
Why?
|
| Time Factors | 3 | 2022 | 1365 | 0.120 |
Why?
|
| Disease Management | 1 | 2016 | 108 | 0.120 |
Why?
|
| Prosthesis Implantation | 1 | 2015 | 28 | 0.120 |
Why?
|
| Supination | 1 | 2014 | 18 | 0.120 |
Why?
|
| Prosthesis Design | 3 | 2022 | 482 | 0.120 |
Why?
|
| Radiotherapy Dosage | 1 | 2015 | 93 | 0.120 |
Why?
|
| Ossification, Heterotopic | 1 | 2015 | 36 | 0.120 |
Why?
|
| Lung | 1 | 2015 | 155 | 0.120 |
Why?
|
| Arthroplasty | 1 | 2016 | 144 | 0.120 |
Why?
|
| Hand Strength | 1 | 2014 | 56 | 0.120 |
Why?
|
| Cartilage, Articular | 2 | 2016 | 407 | 0.120 |
Why?
|
| Wrist Joint | 1 | 2014 | 61 | 0.120 |
Why?
|
| Risk Factors | 2 | 2022 | 2243 | 0.120 |
Why?
|
| Drug Implants | 2 | 2005 | 8 | 0.110 |
Why?
|
| Protein Kinases | 1 | 2014 | 12 | 0.110 |
Why?
|
| Telomerase | 2 | 2004 | 9 | 0.110 |
Why?
|
| Magnetic Resonance Imaging | 2 | 2011 | 1140 | 0.110 |
Why?
|
| Spinal Fusion | 1 | 2020 | 473 | 0.110 |
Why?
|
| Receptors, Notch | 1 | 2013 | 1 | 0.110 |
Why?
|
| Gene Expression Regulation, Neoplastic | 3 | 2014 | 95 | 0.100 |
Why?
|
| Wnt Proteins | 1 | 2013 | 19 | 0.100 |
Why?
|
| Recovery of Function | 2 | 2012 | 279 | 0.100 |
Why?
|
| Bone Matrix | 2 | 2003 | 26 | 0.100 |
Why?
|
| Fibrous Dysplasia of Bone | 1 | 2012 | 3 | 0.100 |
Why?
|
| Injections, Intralesional | 1 | 2012 | 31 | 0.100 |
Why?
|
| beta Catenin | 1 | 2013 | 60 | 0.100 |
Why?
|
| Bone Regeneration | 2 | 2003 | 75 | 0.100 |
Why?
|
| Animals | 5 | 2007 | 3389 | 0.100 |
Why?
|
| Diagnosis, Differential | 2 | 2011 | 342 | 0.100 |
Why?
|
| Positron Emission Tomography Computed Tomography | 2 | 2022 | 27 | 0.100 |
Why?
|
| Fluorodeoxyglucose F18 | 2 | 2022 | 38 | 0.100 |
Why?
|
| Range of Motion, Articular | 1 | 2014 | 688 | 0.090 |
Why?
|
| Ankle | 1 | 2011 | 21 | 0.090 |
Why?
|
| Thoracoscopy | 1 | 2010 | 20 | 0.090 |
Why?
|
| Ilium | 1 | 2010 | 29 | 0.090 |
Why?
|
| Age Factors | 2 | 2019 | 744 | 0.090 |
Why?
|
| Proportional Hazards Models | 2 | 2021 | 326 | 0.090 |
Why?
|
| Predictive Value of Tests | 1 | 2011 | 457 | 0.080 |
Why?
|
| Chicago | 1 | 2012 | 844 | 0.080 |
Why?
|
| Survival Analysis | 1 | 2008 | 235 | 0.070 |
Why?
|
| Compressive Strength | 1 | 2007 | 22 | 0.070 |
Why?
|
| Elasticity | 1 | 2007 | 30 | 0.070 |
Why?
|
| Illinois | 1 | 2008 | 228 | 0.070 |
Why?
|
| Cell Division | 3 | 2022 | 79 | 0.070 |
Why?
|
| Prospective Studies | 2 | 2023 | 1659 | 0.070 |
Why?
|
| Muscle Proteins | 1 | 2006 | 31 | 0.070 |
Why?
|
| Radiation Tolerance | 1 | 2006 | 6 | 0.070 |
Why?
|
| Transcription, Genetic | 1 | 2006 | 91 | 0.070 |
Why?
|
| Cyclin-Dependent Kinase Inhibitor p16 | 1 | 2006 | 21 | 0.070 |
Why?
|
| Proteins | 1 | 2006 | 54 | 0.070 |
Why?
|
| Glycoproteins | 1 | 2006 | 47 | 0.070 |
Why?
|
| Carrier Proteins | 1 | 2006 | 79 | 0.070 |
Why?
|
| Heterocyclic Compounds, 3-Ring | 2 | 2017 | 13 | 0.060 |
Why?
|
| Phosphorylation | 2 | 2016 | 133 | 0.060 |
Why?
|
| Dose-Response Relationship, Drug | 1 | 2005 | 315 | 0.060 |
Why?
|
| Multivariate Analysis | 1 | 2005 | 295 | 0.060 |
Why?
|
| Neoplasm Invasiveness | 2 | 2021 | 77 | 0.060 |
Why?
|
| Blastomycosis | 1 | 2004 | 20 | 0.060 |
Why?
|
| Lower Extremity | 1 | 2023 | 38 | 0.060 |
Why?
|
| Biopsy, Needle | 1 | 2004 | 96 | 0.060 |
Why?
|
| Surgical Flaps | 1 | 2023 | 50 | 0.050 |
Why?
|
| Mutation | 2 | 2021 | 311 | 0.050 |
Why?
|
| Bone Demineralization Technique | 1 | 2003 | 3 | 0.050 |
Why?
|
| Lymphocyte Count | 1 | 2023 | 16 | 0.050 |
Why?
|
| Tumor Microenvironment | 1 | 2023 | 16 | 0.050 |
Why?
|
| Blood Loss, Surgical | 1 | 2023 | 55 | 0.050 |
Why?
|
| Arthroscopy | 1 | 2011 | 906 | 0.050 |
Why?
|
| Lymphocytes | 1 | 2023 | 59 | 0.050 |
Why?
|
| Preoperative Care | 1 | 2023 | 121 | 0.050 |
Why?
|
| Exoribonucleases | 1 | 2002 | 1 | 0.050 |
Why?
|
| Genes, Tumor Suppressor | 1 | 2002 | 10 | 0.050 |
Why?
|
| Saccharomyces cerevisiae Proteins | 1 | 2002 | 10 | 0.050 |
Why?
|
| Necrosis | 1 | 2022 | 26 | 0.050 |
Why?
|
| Bone Resorption | 1 | 2003 | 83 | 0.050 |
Why?
|
| Signal Transduction | 2 | 2016 | 389 | 0.050 |
Why?
|
| Replantation | 1 | 2022 | 8 | 0.050 |
Why?
|
| Drug Delivery Systems | 1 | 2002 | 29 | 0.050 |
Why?
|
| Transplantation Immunology | 1 | 2002 | 2 | 0.050 |
Why?
|
| Tissue and Organ Harvesting | 1 | 2002 | 16 | 0.050 |
Why?
|
| Printing, Three-Dimensional | 1 | 2021 | 9 | 0.050 |
Why?
|
| Forecasting | 1 | 2002 | 91 | 0.050 |
Why?
|
| Time-to-Treatment | 1 | 2022 | 32 | 0.050 |
Why?
|
| Radiopharmaceuticals | 1 | 2022 | 49 | 0.050 |
Why?
|
| High-Throughput Nucleotide Sequencing | 1 | 2021 | 43 | 0.050 |
Why?
|
| Positron-Emission Tomography | 1 | 2022 | 84 | 0.050 |
Why?
|
| Risk Assessment | 1 | 2004 | 622 | 0.050 |
Why?
|
| Neoplasm Grading | 1 | 2021 | 45 | 0.050 |
Why?
|
| SEER Program | 1 | 2021 | 38 | 0.050 |
Why?
|
| Cartilage | 1 | 2002 | 101 | 0.050 |
Why?
|
| DNA Damage | 2 | 2014 | 24 | 0.040 |
Why?
|
| Chronic Disease | 1 | 2002 | 415 | 0.040 |
Why?
|
| Tendons | 1 | 2002 | 214 | 0.040 |
Why?
|
| Biomechanical Phenomena | 1 | 2002 | 639 | 0.040 |
Why?
|
| Enzyme Activation | 2 | 2014 | 103 | 0.040 |
Why?
|
| Tumor Cells, Cultured | 3 | 2004 | 116 | 0.040 |
Why?
|
| Mesna | 1 | 2019 | 3 | 0.040 |
Why?
|
| Ifosfamide | 1 | 2019 | 13 | 0.040 |
Why?
|
| Organ Sparing Treatments | 1 | 2019 | 7 | 0.040 |
Why?
|
| Leg | 1 | 2019 | 48 | 0.040 |
Why?
|
| Doxorubicin | 1 | 2019 | 54 | 0.040 |
Why?
|
| Arm | 1 | 2019 | 80 | 0.040 |
Why?
|
| Pyrazines | 1 | 2017 | 10 | 0.040 |
Why?
|
| Drug Synergism | 1 | 2017 | 38 | 0.040 |
Why?
|
| Receptor Cross-Talk | 1 | 2016 | 6 | 0.030 |
Why?
|
| Kaplan-Meier Estimate | 1 | 2015 | 161 | 0.030 |
Why?
|
| Checkpoint Kinase 1 | 1 | 2014 | 5 | 0.030 |
Why?
|
| Cell Cycle Checkpoints | 1 | 2014 | 5 | 0.030 |
Why?
|
| RNA Interference | 1 | 2014 | 29 | 0.030 |
Why?
|
| Gene Knockdown Techniques | 1 | 2014 | 42 | 0.030 |
Why?
|
| RNA, Small Interfering | 1 | 2014 | 68 | 0.030 |
Why?
|
| Hedgehog Proteins | 1 | 2013 | 6 | 0.030 |
Why?
|
| Culture Techniques | 1 | 1992 | 15 | 0.030 |
Why?
|
| Extracellular Matrix Proteins | 1 | 1992 | 47 | 0.020 |
Why?
|
| Proteoglycans | 1 | 1992 | 128 | 0.020 |
Why?
|
| Acridine Orange | 1 | 2006 | 1 | 0.020 |
Why?
|
| Radiation-Sensitizing Agents | 1 | 2006 | 5 | 0.020 |
Why?
|
| Intracellular Signaling Peptides and Proteins | 1 | 2006 | 45 | 0.020 |
Why?
|
| Gamma Rays | 1 | 2006 | 16 | 0.020 |
Why?
|
| Down-Regulation | 1 | 2006 | 92 | 0.020 |
Why?
|
| Adaptor Proteins, Signal Transducing | 1 | 2006 | 61 | 0.020 |
Why?
|
| Cell Survival | 1 | 2006 | 111 | 0.020 |
Why?
|
| Manubrium | 1 | 2004 | 2 | 0.010 |
Why?
|
| Sternoclavicular Joint | 1 | 2004 | 6 | 0.010 |
Why?
|
| Chondrocytes | 1 | 2004 | 147 | 0.010 |
Why?
|
| Models, Animal | 1 | 2003 | 106 | 0.010 |
Why?
|
| Biomarkers, Tumor | 1 | 2004 | 179 | 0.010 |
Why?
|
| DNA, Complementary | 1 | 2002 | 23 | 0.010 |
Why?
|
| Microscopy, Phase-Contrast | 1 | 2002 | 5 | 0.010 |
Why?
|
| Telomere | 1 | 2002 | 5 | 0.010 |
Why?
|
| DNA Mutational Analysis | 1 | 2002 | 49 | 0.010 |
Why?
|
| DNA-Binding Proteins | 1 | 2004 | 254 | 0.010 |
Why?
|
| Base Sequence | 1 | 2002 | 89 | 0.010 |
Why?
|
| RNA, Messenger | 1 | 2002 | 264 | 0.010 |
Why?
|
| Disease Models, Animal | 1 | 2003 | 568 | 0.010 |
Why?
|
| Sepharose | 1 | 1992 | 4 | 0.010 |
Why?
|
| Alginates | 1 | 1992 | 5 | 0.010 |
Why?
|
| Hexuronic Acids | 1 | 1992 | 5 | 0.010 |
Why?
|
| Glucuronic Acid | 1 | 1992 | 5 | 0.010 |
Why?
|
| Keratan Sulfate | 1 | 1992 | 15 | 0.010 |
Why?
|
| Gels | 1 | 1992 | 13 | 0.010 |
Why?
|
| Lectins, C-Type | 1 | 1992 | 47 | 0.010 |
Why?
|
| Microspheres | 1 | 1992 | 22 | 0.010 |
Why?
|
| Cattle | 1 | 1992 | 117 | 0.010 |
Why?
|
| Extracellular Matrix | 1 | 1992 | 47 | 0.010 |
Why?
|
| Aggrecans | 1 | 1992 | 52 | 0.010 |
Why?
|
| Cells, Cultured | 1 | 1992 | 475 | 0.010 |
Why?
|